The Impact of Sequencing the Medical Genome for Specifically Identifying, Preventing and Treating Horrendous Diseases Such as Cancers

Human Genome sequence (which serves as Reference Sequence) contains the sequence of the entire book of life, but the medical genome will sequence only the strip of DNA in the cancer cell genome which carry oncogene responsible for a specific disease. The Cancer Genome Atlas Project initially focused on identifying important deleterious genetic changes involved in Lung, Brain, Breast and Ovarian cancers and later investigation will include other cancers. When we sequence a single breast cancer cell and compare with the Reference Sequence, we found two deleterious mutations on Chromosore-17. Chrosome-17 is long chromosome it contains 92 million nucleotide bases and carries 1,394 genes. About 11 somatic mutations are discovered. Of the two deleterious mutations, the first is the mutation on BRCA1 gene responsible for causing breast cancer in both men and women. The second one is the BRCA2 gene responsible for causing prostate cancer in men. We first find a cure in animal then we translated the animal work in human. From the Structure Activity relationship, I have demonstrated that 1-Aziridine, 2,4-dinotrobenzamide (CB1954) showed the highest biological activity against a solid aggressive tumor like, Walker Carcinoma 256 in Rats. I translated this work in human by making AZQ. Of all the deadly cancers, the deadliest are Brain, Breast and Lungs. Brain cancer is the worst. Most patients die with in fourteen months of their diagnosis. By making AZQ (US Patent 4,233,215) to attack Glioblastoma, the Brain tumor, I used Quinone to transport two aziridines and two carbamates’ molecules attached to Quinone across the Blood Brain Barrier (BBB). AZQ is a pro-drug. It is activated in the presence of acid. As the glioblastoma grows, it uses glucose as a source of energy. Glucose is broken down to Lactic Acid. It is the acid which activate Aziridine and Carbamate molecules to generate the most powerful Carbonium ions which attack the growing Glioblastoma tumor which starts shrinking. Most untreated patients die within fourteen months. The treated patients are most likely to live 2-years longer. The residual cell could be treated by immune therapy. Literature search showed that AZQ is extensively studied. To shut off a gene, two methods are available. One was developed by Professor Ross of London University by using Nitrogen Mustard which cross-link both strands of DNA. As his student, I used Aziridine, half as toxic, to bind to one strand of DNA shutting off the gene. Both methods are presented below.